Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M

被引：0
|
作者：
Zhang, Xiaoying [1 ]
机构：
[1] Shandong Univ, Qilu Hosp, Dept Geriatr, Jinan 250012, Peoples R China
来源：
GLOBAL MEDICAL GENETICS | 2021年 / 08卷 / 04期
关键词：
D O I：
10.1055/s-0041-1731067
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
引用
收藏
页码：133 / 134
页数：2
相关论文
共 50 条
  • [1] Osimertinib Depletes EGFR T790M in the Spinal Fluid of Patients with Carcinomatous Meningitis of Lung Adenocarcinoma Harboring De Novo EGFR T790M
    Senoo, Satoru
    Ohashi, Kadoaki
    Nishii, Kazuya
    Hara, Naofumi
    Kano, Hirohisa
    Ninomiya, Kiichiro
    Maeda, Yoshinobu
    Kiura, Katsuyuki
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (08) : E140 - E142
  • [2] In vivo efficacy of triplet therapy with osimertinib, cetuximab and bevacizumab for lung cancer cells harboring EGFR T790M
    Nishii, Kazuya
    Ohashi, Kadoaki
    Makimoto, Go
    Higo, Hisao
    Ninomiya, Kiichiro
    Kayatani, Hiroe
    Ninomiya, Takashi
    Kubo, Toshio
    Rai, Kammei
    Ichihara, Eiki
    Hotta, Katsuyuki
    Tabata, Masahiro
    Kiura, Katsuyuki
    CANCER RESEARCH, 2018, 78 (13)
  • [3] Loss of T790M Mutation is Associated with Early Progression to Osimertinib in Chinese Advanced NSCLC Patients Harboring EGFR T790M
    Zhao, S.
    Jiang, T.
    Li, X.
    Zhao, C.
    Su, C.
    Ren, S.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S410 - S410
  • [4] Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M
    Zhao, Sha
    Li, Xuefei
    Zhao, Chao
    Jiang, Tao
    Jia, Yijun
    Shi, Jinpeng
    He, Yayi
    Li, Jiayu
    Zhou, Fei
    Gao, Guanghui
    Li, Wei
    Chen, Xiaoxia
    Su, Chunxia
    Ren, Shengxiang
    Zhou, Caicun
    LUNG CANCER, 2019, 128 : 33 - 39
  • [5] Osimertinib for lung cancer cells harboring low-frequency EGFR T790M mutation
    Joshi, Asim
    Butle, Ashwin
    Hait, Supriya
    Mishra, Rohit
    Trivedi, Vaishakhi
    Thorat, Rahul
    Choughule, Anuradha
    Noronha, Vanita
    Prabhash, Kumar
    Dutt, Amit
    TRANSLATIONAL ONCOLOGY, 2022, 22
  • [6] Effects of vandetanib on lung adenocarcinoma cells harboring an EGFR T790M mutation in vivo
    Ichihara, Eiki
    Ohashi, Kadoaki
    Takigawa, Nagio
    Osawa, Masahiro
    Takeda, Hiromasa
    Ochi, Nobuaki
    Harada, Daijiro
    Yasugi, Masayuki
    Tanimoto, Mitsune
    Kiura, Katsuyuki
    CANCER RESEARCH, 2009, 69
  • [7] Effective clinical response of lung adenocarcinoma harboring EGFR 19Del/T790M/in cis-C797S osimertinib to osimertinib and gefitinib combination therapy
    Wang, Yanyan
    Jiang, Chenchen
    Tang, Mingyue
    Li, Huiyuan
    Zhao, Cancan
    Zhao, Menglin
    Zhang, Yue
    Li, Xinwei
    Mi, Jiaqi
    Shen, Honghong
    Wang, Zishu
    Su, Fang
    QUANTITATIVE IMAGING IN MEDICINE AND SURGERY, 2023, 13 (08) : 5362 - 5368
  • [8] Predictive Factors of Osimertinib as Salvage Treatment for Metastatic EGFR T790M Positive Lung Adenocarcinoma
    Jang, S. H.
    Park, J. Y.
    Hwang, Y. I.
    Kim, H. Y.
    Seo, J. W.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S830 - S830
  • [9] PREDICTIVE FACTORS OF OSIMERTINIB AS SALVAGE TREATMENT FOR METASTATIC EGFR T790M POSITIVE LUNG ADENOCARCINOMA
    Park, Ji Young
    Jang, Seung Hun
    Kim, Hwan Il
    Kim, Joo-Hee
    Park, Sunghoon
    Hwang, Yong Il
    Jung, Ki-Suck
    Seo, Jinwon
    RESPIROLOGY, 2019, 24 : 177 - 177
  • [10] Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR
    Sakai, Hitomi
    Hayashi, Hidetoshi
    Iwasa, Tsutomu
    Hasegawa, Yoshikazu
    Takeda, Masayuki
    Nakagawa, Kazuhiko
    ESMO OPEN, 2017, 2
12345